What's breaking now, across thousands of outlets.
Plus, news about Merck KGaA, Rezolute, Vir, Orakl and Cellectis. Regeneron’s mid-stage POTS data: The biotech’s monoclonal antibody, baloncibart, given at 450 mg led to an average 11.4-beat-per-minute reduction in heart ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Liquid biopsies already help guide treatment, but researchers wanted to see if they can be used to diagnose people too.
The Kano State Commissioner for Health has disclosed that no fewer than 17,000 children have been diagnosed with pneumonia in the state.
The Maryland Democrat, who's the ranking member of the Senate Foreign Relations Subcommittee, just announced he's going to run for Majority Leader. He spoke to NPR about his foreign aid vision.
Researchers have created a hybrid malaria parasite that combines the manufacturing advantages of the strain used in every current whole-parasite malaria vaccine with the much higher liver infectivity of a parasite collected recently in East Africa. The work is published in JCI Insight.
